2016 CJASN--Urinary Biomarkers at the Time of AKI Diagnosis as Predictors of Progression of AKI among Patients with Acute Cardiorenal Syndrome

2016 CJASN--Urinary Biomarkers at the Time of AKI Diagnosis as Predictors of Progression of AKI among Patients with Acute Cardiorenal Syndrome

The primary outcome: AKI progression
The secondary outcome: AKI progression with subsequent death

Conclusions uAGT, uNGAL, and uIL-18 measured at time of AKI diagnosis improved risk stratification and identified CRS patients at highest risk of adverse outcomes.

=> Best ROC: uAGT => 0.76 in primary outcome/ 0.93 in secondary outcome

Calcinosis cutis

Henoch Scholein Purpura, HSP, with renal invovlement

暫定的題目

五個主題：

1. Better proteinuria control for preserve renal function

2. Renoprotection

3. Regeneration for the kidney 

4. Update of AKI

5. Hypertension, The Nephrologist View

Hypothyroidism, Pseudo, Pseudo-Pseudo

Wikipedia好像整理得不錯：（應該沒錯吧？）

https://www.wikiwand.com/en/Pseudopseudohypoparathyroidism

Hypoparathyroidism
Pseudo-hypoparathyroidism
Pseudo-Pseudo-hypoparathyroidism

1. "假"：有Imprint 的概念，GNAS1裡的一個locus
    "假"：有分1a, 1b, 2
2. 外觀異常只有"假1a"和"假假"
3. "假": 抽血全都異常：高雙P (PTH/Pi)＋低雙C(Calcitriol/Ca)
"假假"：抽血全都正常！只是長得不一樣
4. hypo-PTH: low PTH/Calcitriol/Ca，但是高Pi
5. 背genetic defect from whom: 母親or父親

2016 RRT trial: ELAIN vs. AKIKI

From 2016 JAMA--ELAIN trial

	NEJM--AKIKI (multicenter)	JAMA--ELAIN trial (single center)
Hypothesis	We hypothesized that the "delayed" strategy would prove beneficial to the patients and would translate into increased survival. The study is designed to prove superiority (and not noninferiority) of this strategy over the "early" one.	We hypothesize that an early initiation of RRT decreases the 90-day mortality from all causes compared to late onset of RRT.
Study population	RIFLE F: early and late (or with alert criteria)	AKIN 2 and 3 (3 or absolute indication)
AKI definition	RIFLE F: early or late	AKIN stage: 2 or 3
Intervention	Arm 1: RRT immediately when a RIFLE F status is documented Arm 2: RRT in patient with RIFLE F only in case of occurrence of one or more of the follow events (“Alert Criteria”)	Arm 1: Early initiation of RRT (AKIN 2) Arm 2: Late initiation of RRT (AKIN 3 or absolute indication for RRT)
Primary outcome	Overall survival, measured from the date of randomization to the date of death, regardless of the cause. Minimun duration: 60-day follow-up	Overall survival in a 90-day follow up period (90-day all cause mortality)
Secondary outcome	survival rate at D28 % of patients requireing who did not require RRT in the delayed strategy timie unitl cessation of RRT therapy Rate of adverse events potentially related to the AKI or to RRT (eg; RRT catheter related complicates, hemorrhage due to anticoagulation required for RRT etc…) rate of nosocomial infections # of vetilator free days of RRT free days and of vasopressors free days length of stay in ICU and hospital rate of limitations of treatment for futiligy total cost of connsumables (including RRT catheters and lines among others) related to RRT between D1 and D28	Length of ICU stay Length of hospitalization Duration of RRT Recovery of renal fx by D28 60-d and 1-yr all cause mortality SOFA score at D1-14,21,28 cost adnlysis of RRT Incidence of complication due to RRT
Inclusion criteria	ICU patients Age > = 18 years AKI compatible with the dx of ATN defined by clinical ischemic or toxi insult AKI, with RIFLE F classification: (one of the following 3) Creatinine > 354 mmol/L (4mg/dL) or > 3 times the baseline anuria for more than 12 hours oliguria defined as U/O < 0.3ml/kg/hr or 500ml/d for more than 24 hours Mechanical ventilation and/or catecholamines infusion (noradrenaline or/and adrenaline)	AKI: AKIN 2 despite optimal resuscitation Plasma NGAL > 150ng/mL at least one of the following conditions severe sepsis, use of catecholamines > 0.1ug/mkg/min, refractory fluid overload, non-renal SOFA> = 2 age 18~90 y/o intention to provide full intensive care tx for at least > 3-d existence of informed consent
Exclusion criteria	CKD (defined as creatinine clearance < 30ml/min) Patients already enrolled in the study Inclusion criteria #4 present for more than 5 hours AKI due to urinary tract obstruction renal vessels obstruciton tumor lysis syndrome thrombotic microangiopathy acute GN Intoxication with a dialyzable product Child-Pugh class C liver cirrhosis Renal transplant Cardiac arrest without awakening at time of potential inclusion Moribund state decision to limit treatment RRT already started for the current episode of AK Presenting (at time of potential inclusion) a strong indication for immediate RRT oligoanuria for more than 3 days Alert criteria Under cardiopulmonary bypass Included in another clinical trial on RRT modalities	pre-exsting kidney dx w/o RRT (GFR < 30 ml/min) p’t w/ previous RRT experience AKI due to permanent occlusion or surgical lesion of the renal artery AKI due to GN, interstitial nephritis, or vasculitis AKI caused by postrenal obstruction HUS/TTP Pregnancy prior kidney Tx HRS AIDS w/ CD4 < 50/uL hema malig. w/ ANC < 50/uL no HF machine free for use at the moment of inclusion
Conclusions:	In a trial involving critically ill patients with severe acute kidney injury, we found no significant difference with regard to mortality between an early and a delayed strat- egy for the initiation of renal-replacement therapy. A delayed strategy averted the need for renal-replacement therapy in an appreciable number of patients.	AmongcriticallyillpatientswithAKI,early RRT compared with delayed initiation of RRT reduced mortality over the first 90 days. Further multicenter trials of this intervention are warranted.

2016 AJKD--Continuous Dialysis Therapies Core Curriculum 2016--CRRT principle

2016 AJKD--Continuous Dialysis Therapies Core Curriculum 2016--CRRT principle

1. Studies designed to compare continuous versus intermittent therapies have not shown a beneficial effect on mortality
2. With greater hemodynamic stability and a higher likelihood of kidney recovery compared to standard iHD
3. Lack of consensus on several aspects of RRT (eg, timing of initiation, dose, session lenth, and standards for monitoring.

===================================================================

1. Solute transport
1. convection, diffusion, and adsorption, and replenishing depleted solutes
2. CVVH, relies solely on convection; CVVHD, CVVHDF, SCUF

3. These mechanisms can by manipulated by the type of membrane and blood and fluid flow rates to selectively influence solute clearances of moledules of different size.

Adsorption of solutes occurs to varying degrees in all CRRT circuits and can be a contributor for large molecule removal, depending on membrane characteristics.

4. Effluent flow rate (Qef) is the final result of the filtration process and is composed of the net ultrafiltration (Qnet) + substitution fluid rate (Qs) in CVVH and CVVHDF + dialysate flow rate in CVVHD and CVVHDF.

=> CVVH and CVVHDF: Qef = Qnet + Qs

=> CVVHD and CVVHDF: Qef = Qnet + Qs + dialysate flow rate (????)

• Filter clearance for most CRRT = Qef * S
• S: sieving coefficient = Cuf / Cp, regulated by reflection coefficient of membranes
• reflection coefficient of memebranes => S = 1 - σ, S = 1, solute freely passes through membrane; S = 0, solute cannot freely pass through membrane
• For middle molecules: clearance depends on [membrane permeability] * UF volume
• For adsorption: overall blood clearance can be grater than filter clearance, even when S is low => blood-side clearances will not match filter clearances

5. Techniques: differ in [various driving force for solute removal] and [membrane use]
1. CVVH: via convection, driven by TMP:
1. Uf  = Kf * TMP,
1. Kf = coefficient of hydraulic permeability, and
2. TMP = (Pb - Puf) - 𝝿, Pb = blood hydrostatic pressure; Puf = UF/dialysate hydrostatic pressure, 𝝿 = plasma proteins oncotic pressure
2. Cx = Quf * S, Cx: convection clearance, S: sieving characteristics of membane = Cuf/Cp
3. Qnet = UF - substitution fluid infusion
2. CVVHD: vis diffusive clearance, by solute concentration gradient acrosss the dialysis membrane
1. Sd = (Cg / Mt ) * D * T * A
2. Sd: solute diffusion, Cg: concentration gradient, Mt = membrane thickness, D = diffusion coefficient of the solute, T = solution temperature, A = membrane surface area
3. gradient across membranes: Qd、Qb; Qd is the rate limiting factor for solute removal => Qd 0.5~3 L/h (8~50 mL/min) vs. Qb 100~200 mL/min
3. CVVHDF: via diffusion + convective technique => dialysate + substitution sol.
1. removal of small + middle molecules
4. Slow continuous ultrafiltration (SCUF): use exclusively the principle of UF w/o substitution. => safely treat fluid overload
1. solute removal is minimal because it is limited by total UF volume
6. CRRT: plasma composition + fluid amout in the body => 分開處理

Substitiuion fluid:

7. Citrate is used as an anticoagulant => provides a buffer base cecause each citrate colecule is metabolized in the liver and muscle to 3 molecules of bicarbonate

=> but  may leads to markedly hypotensiion

8. CRRT’s key feature is the flexibility in maintaining a specific level of any electrolyte and calibrating the rate of correction to accommodate the clinical need
9. The technique to achieve fluid management:
1. Most common: vary Qnet to meet the anticipated fluid balance needs over 8~24 hours:
1. Effluent vol + solute clearance => vary with each adjustment in net ultrafiltration
2. To keep a fixed rate of UF exceeds the hourly intake from all sources and to vary the amount of post-dilution substitution fuid administered:
1. ensures a constant effluent volumen and solute clearance level.
2. Post-dilution fluid can be given outside the CRRT circuit through a peripheral IV line.
3. Third method: fluid valance is tailored to achieve a targeted hemodynamic parameter every hour.
1. such as: CVP, MAP, PAWP, etc.